Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters on the deal. Verona Pharma plc (Nasdaq: VRNA) announced that the U.S. Food and Drug...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
You must be a Standard 1 Year member to access this content.
Covington advised Bristol Myers Squibb on the transaction, while Cooley and Wilson Sonsini Goodrich & Rosati advised RayzeBio Inc. Goodwin advised Centerview Partners in its role...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction. Verve Therapeutics, Inc. (Nasdaq:VERV) announced the expansion of its relationship with Eli Lilly...
You must be a Standard 1 Year member to access this content.
White & Case and Wilson Sonsini Goodrich & Rosati advised Azurity Pharmaceuticals, Inc., and Kirkland & Ellis advised Slayback Pharma LLC on the transaction. Azurity Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve on IP matters related to the transaction. Verve Therapeutics, Inc., a clinical-stage genetic medicines company, announced an exclusive research collaboration...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised RayzeBio on the deal. RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced a $160 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Azurity on the deal while King & Spalding represented Arbor Pharmaceuticals. Azurity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Acumen Pharmaceuticals on the deal. Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
You must be a Standard 1 Year member to access this content.
